Life Sciences

Watson for Drug Discovery Identifies Proteins Associated with Cardiovascular Disease

Share this post:

Capsule close-up.

Heart attack and stroke are 2 of the top 10 causes of death worldwide. Identifying the proteins involved in each of them is the beginning of a journey to understanding how these diseases develop. In a novel experiment presented at the American Heart Association Scientific Sessions on November 12, 2017, and published in a supplement of the journal Ciruculation, cardiology researchers tested Watson’s ability to rank proteins they knew were associated with cardiovascular disease. In the experiment, researchers gave Watson a list of 1,274 proteins associated with many diseases, some of which the researchers knew were associated with atherosclerosis and heart failure to see if Watson could identify them.

Watson used a training sample of proteins known to be associated with atherosclerosis and heart failure to rank the remaining proteins, by comparing literature fingerprints. Watson ranked the cardiovascular proteins significantly higher than non-cardiovascular proteins and its predictive ability improved with increased specificity of training on the cardiovascular disease phenotypes of coronary atherosclerosis and heart failure. These data demonstrate that Watson for Drug Discovery does have the ability to help researchers by classifying proteins associated with cardiovascular disease and that the predictive ability is honed with increasing specificity of disease phenotype.1

The next step will include analyzing blood samples taken from about 20,000 patients to evaluate whether Watson can successfully identify new proteins for researchers that have not previously been associated with heart failure and atherosclerosis. Congratulations to Scott Spangler and Alix Lacoste for their work in demonstrating Watson’s capabilities in cardiovascular disease discovery.

1. Christian T Ruff, Alix Lacoste, Francesco Nordio, Christina L Fanola, Michael G Silverman, Elenee Argentinis, Scott Spangler, Marc S Sabatine. Classification of Cardiovascular Proteins Involved in Coronary Atherosclerosis and Heart Failure Using Watson’s Cognitive Computing Technology. Circulation. 2017;136:A16678

 

 

More Life Sciences stories

Providers weigh the impact of value-based payment models on population health

Written by David Jackson | Blog Post, Value-Based Care

To get some insight into how providers are handling the transition and how it has influenced their population health strategies, the HealthLeaders Media Intelligence Unit, in conjunction with IBM Watson Health, conducted the 2018 Population Health Survey. ...read more


Watson Health: Get the Facts

Written by Watson Health | Cognitive Computing, Drug Discovery, Oncology & Genomics

Watson is the only AI technology tackling a wide range of the world’s biggest healthcare challenges including cancer, diabetes, drug discovery and more. In oncology, Watson is at work supporting cancer care in more than 150 hospitals in 11 countries, and a large, growing body of evidence supports the use of Watson in healthcare. ...read more


IBM Watson Health Names 50 Top Cardiovascular Hospitals

Written by Ekta Punwani | Blog Post, Value-Based Care

This is the 20th year of our 50 Top Cardiovascular Hospitals™ annual study. The winning hospitals in our study have demonstrated this with better outcomes at a lower cost per case than non-winning hospitals. ...read more